Payment overview · 2025
General Payments
$475.79
37 reported records · 10 companies
Healthcare provider profile · identity verified
Sara S Graybill, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRAND ISLAND, NE · NPI 1932152907
Verified facts
What the public records show
CMS Open Payments records show Sara S Graybill, M.D. received $475.79 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $206.77 | 43.5% | 21 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.44 | 15.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.01 | 8.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $33.89 | 7.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.10 | 6.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.05 | 4.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.49 | 4.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.21 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.89 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.94 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $475.79 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.13 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.89 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.44 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.10 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.54 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $22.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.49 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 58 |
| Omeprazole | Omeprazole | 297 | 61 |
| Alendronate Sodium | Alendronate Sodium | 247 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 46 |
| Losartan Potassium | Losartan Potassium | 221 | 54 |
| Lisinopril | Lisinopril | 218 | 42 |
| Gabapentin | Gabapentin | 212 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 33 |
| Montelukast Sodium | Montelukast Sodium | 194 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 45 |
| Tramadol Hcl | Tramadol Hcl | 157 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 35 |
| Potassium Chloride | Potassium Chloride | 145 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 24 |
| Trazodone Hcl | Trazodone Hcl | 135 | 24 |
| Sertraline Hcl | Sertraline Hcl | 130 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 20 |
| Furosemide | Furosemide | 116 | 29 |
| Farxiga | Dapagliflozin Propanediol | 112 | 11 |
| Meloxicam | Meloxicam | 100 | 23 |
| Metformin Hcl Er | Metformin Hcl | 100 | 20 |
| Eliquis | Apixaban | 99 | 12 |
| Metformin Hcl | Metformin Hcl | 94 | 26 |
| Ozempic | Semaglutide | 94 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 21 |
| Bupropion Xl | Bupropion Hcl | 75 | 16 |
| Pregabalin | Pregabalin | 75 | 14 |
| Simvastatin | Simvastatin | 75 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 15 |
| Jardiance | Empagliflozin | 66 | suppressed |
| Allopurinol | Allopurinol | 63 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 13 |
| Carvedilol | Carvedilol | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 15 |
| Prednisone | Prednisone | 61 | 34 |
| Alprazolam | Alprazolam | 59 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 11 |
| Lorazepam | Lorazepam | 56 | 12 |
| Spironolactone | Spironolactone | 55 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 22 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Cephalexin | Cephalexin | 45 | 20 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Famotidine | Famotidine | 43 | 11 |
| Linzess | Linaclotide | 42 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | suppressed |
| Cefdinir | Cefdinir | 35 | 23 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 31 | 31 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 21 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Levonorgestrel-Eth Estradiol | Levonorgestrel/Ethin.Estradiol | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Atenolol | Atenolol | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 17 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $475.79 · 37 records | ABBVIE INC. | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, REZDIFFRA, ROTATEQ, Rybelsus, UBRELVY, VAXNEUVANCE, VIBERZI, VOQUEZNA, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error